知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

1219 条记录 (耗时 0.039 秒)

    Protein product for treatment of infectious diseases and related inflammatory processes
    31.
    发明授权
    Protein product for treatment of infectious diseases and related inflammatory processes 失效
    用于治疗感染性疾病和相关炎症过程的蛋白质产品

    公开(公告)号：US08691752B2

    公开(公告)日：2014-04-08

    申请号：US12593140

    申请日：2008-03-27

    申请人： Maria Rosa Sarrias Fornés ,  Francisco Lozano Soto

    发明人： Maria Rosa Sarrias Fornés ,  Francisco Lozano Soto

    IPC分类号： A61K38/00 ,  A61K39/38 ,  A61P31/10 ,  A61P5/00 ,  A01N37/18

    CPC分类号： A61K38/1774

    摘要： The inventors have found that CD6, a member of the Scavenger Receptor Cysteine-Rich (SRSR) superfamily expressed on human lymphocytes binds to Gram-positive and Gram-negative bacteria, as well as to other microbial structures. Thus, a CD6 product is useful for the manufacture of a medicament for therapeutic and/or preventive treatment of an infectious disease or of an inflammatory condition related to an infectious disease or to the presence of a product derived from an infectious agent in a mammal including a human. Examples of such inflammatory conditions are systemic inflammatory response syndrome (SIRS), sepsis, severe sepsis and septic shock.

    摘要翻译： 发明人已经发现，CD6，在人淋巴细胞上表达的清除剂受体半胱氨酸（SRSR）超家族的成员结合革兰氏阳性和革兰氏阴性细菌以及其它微生物结构。 因此，CD6产品可用于制造用于治疗和/或预防治疗感染性疾病或与感染性疾病相关的炎性病症或来自哺乳动物感染因子的产品的存在的药物，包括 一个人。 这种炎性病症的实例是全身炎症反应综合征（SIRS），败血症，严重败血症和败血性休克。

    Method for site-specific polyvalent display on polymers
    32.
    发明授权
    Method for site-specific polyvalent display on polymers 有权
    聚合物上位点特异性多价显示的方法

    公开(公告)号：US08524663B2

    公开(公告)日：2013-09-03

    申请号：US11714066

    申请日：2007-03-05

    申请人： Kent Kirshenbaum ,  Justin M. Holub

    发明人： Kent Kirshenbaum ,  Justin M. Holub

    IPC分类号： A61K38/02 ,  A61P5/00 ,  C07K2/00 ,  C07K1/00

    CPC分类号： A61K47/48315 ,  A61K47/641 ,  C07K1/1077

    摘要： The present invention relates to novel complex peptidomimetic products comprising multiple homogeneous or heterogeneous pendant groups that are site-specifically positioned along a linear oligomer or polymer scaffold and methods of making thereof. More specifically, the invention relates to N-substituted glycine peptoid oligomers or peptoids and their use as substrates for azide-alkyne [3+2]-cycloaddition conjugation reactions and subsequent additional rounds of oligomerization and cycloaddition. The methods of the invention may also be used to generate peptoid-peptide hybrid or peptide products comprising multiple homogeneous or heterogeneous pendant groups, which are positioned precisely along the linear oligomer or polymer scaffold.

    摘要翻译： 本发明涉及新的复合肽模拟产物，其包含沿着线性低聚物或聚合物支架位点特异性定位的多个均相或异构侧基及其制备方法。 更具体地，本发明涉及N-取代的甘氨酸类似物低聚物或拟肽，并且它们用作叠氮炔 - 炔[3 + 2] - 环加成偶联反应和随后的另外一轮低聚和环加成的底物。 本发明的方法还可用于产生包含多个均质或异构侧基的拟肽 - 肽杂交体或肽产物，其准确地沿着线性低聚物或聚合物支架定位。

    GROWTH HORMONE FUSION PROTEINS
    37.
    发明申请
    GROWTH HORMONE FUSION PROTEINS 失效
    生长激素融合蛋白

    公开(公告)号：US20130023477A1

    公开(公告)日：2013-01-24

    申请号：US13620004

    申请日：2012-09-14

    申请人： Richard Ross ,  Peter Artymiuk ,  Jon Sayers

    发明人： Richard Ross ,  Peter Artymiuk ,  Jon Sayers

    IPC分类号： A61K38/27 ,  C07K14/61 ,  C12N1/00 ,  C12N1/19 ,  C12N1/15 ,  C12N5/10 ,  C12N15/18 ,  A61P5/00

    CPC分类号： C07K14/61 ,  C07K14/71 ,  C07K2319/31 ,  C12N15/62

    摘要： We disclose growth hormone [GH] fusion proteins that have increased in vivo stability and activity; nucleic acid molecules encoding said proteins and methods of treatment of growth hormone deficiency that use said fusion proteins. The GH fusion proteins comprise human GH covalently linked to the extracellular domain of Growth Hormone Receptor [GHR] either as a direct in-frame translational fusion or via a flexible peptide linker. The GH/GHR fusion proteins have exceptional pharmacokinetics and are potent growth hormone receptor agonists. The GH/GHR fusion proteins form head to tail dimers.

    摘要翻译： 我们公开了增加体内稳定性和活性的生长激素[GH]融合蛋白; 编码所述蛋白质的核酸分子和使用所述融合蛋白的生长激素缺乏症的治疗方法。 GH融合蛋白包括与生长激素受体[GHR]的细胞外结构域共价连接的人GH，作为直接的帧内翻译融合或通过柔性肽接头。 GH / GHR融合蛋白具有特殊的药代动力学，是有效的生长激素受体激动剂。 GH / GHR融合蛋白形成头对尾二聚体。